Cost Effectiveness Analysis of Combination Treatment Zidovudin, Lamivudin, Nevirapin and Combination Tenofovir, Lamivudin, Efavirenz HIV/AIDS Patients in Bekasi Hospital

COST EFFECTIVENESS ANALYSIS OF ZIDOVUDIN, LAMIVUDIN, NEVIRAPIN (AZT (300)/3TC (150) / NVP (200)) AND TENOFOVIR, LAMIVUDIN, EFAVIRENZ (TDF (300) / 3TC (150) / 3TC (150) / NVP (200)) AND TENOFOVIR, LAMIVUDIN, EFAVIRENZ (TDF (300) / 3TC (150) / 3TC (150) / NVP (200)) / AIDS IN BEKASI HOSPITAL

  • Yusi Anggriani fakultas farmasi universitas pancasila
  • Fredrick Dermawan Purba Fakultas Psikologi, Universitas Padjajaran
  • Reise Manninda Universitas Pancasila
  • Tarsinah Tarsinah Universitas Pancasila
DOI: https://doi.org/10.35814/jifi.v18i2.905

Abstract

HIV/AIDS has become a global issue in many countries. The implementation of ARV / HAART
programs is always changing, due to clinical reasons, population factors, and aff ordability. Pharmacoeconomic studies can be one of the considerations in the policy process for procurement and selection of therapy regimens. The aims of this study were to determine the eff ectiveness of treatment based on CD4 increase and cost eff ectiveness analysis of HAART A and HAART B treatment regimens. This study used a cross sectional observation method. Retrospective data collection and non-experimental observation where conducted followes by a quantitative descriptive analysis according to the patient's perspective to obtain costeffectiveness data. Data were statistically analyzed to obtain the cost-eff ectiveness of treatment. The results showed that the cost-eff ectiveness analysis (CEA) of two regimens found that HAART A was more dominant than HAART B with a signifi cant diff erence p<0.05. While ACER regimen HAART A (16,227) was greater than the value ACER therapy B (28,330.7).

References

1. Peraturan Menteri Kesehatan Republik Indonesia, Pedoman
Pengobatan Antiretroviral no. 87, tahun 2014

2. WHO, HIV/AIDS: Fact Sheet. Retrieved September
25, 2017, from http/www.who.int/mediacentre/
factsheetsfs360/en/. Dalam Yuliandra Yori, Terapi
Antiretroviral pada Pasien HIV AIDS di RSUP Dr. M
Djamil Padang: Kajian Sosiodemografi dan Evaluasi
Obat, Jurnal Sains Farmasi dan Klinis, 2017

3. Kemenkes RI, WHO. 2017. Kajian Nasional respon
HIV Di Bidang kesehatan Republik Indonesia. Kemenkes
RI.

4. Laporan Situasi Perkembangan HIV AIDS & Penyakit
Infeksi Menular Seksual (PIMS) Januari - Desember
2017, Maret ,2018, Dirjen Pencegahan & Pengendalian
Penyakit, Kemenkes RI

5. Mariam S. Perbandingan respon imunologi empat
kombinasi antiretroviral berdasarkan kenaikanjumlah
CD4 di rumah sakit Dr. H. Marzoeki Mahdi Bogor,
periode Mare 2006-2010. Depok: Universitas Indonesia.
2010.

6. Pillay Prinitha, Ford Nathan, Shubber Zara, Ferrand
RA. Outcomes for Efavirenz versus Nevirapine containing
regimens for treatment of HIV-1 infection:
a systematic review and meta-analysis. Plos One.
2013.8(7):e68995.

7. Wong N. Lee M, Lee P, Lee S. Diff erential patternsof
CD4 recovery following eff ective treatmentwith
HAART. J Int AIDS Soc. 2012.15(4):18193.

8. Laporan ART Klinik VCT RSUD Kota Bekasi per
Januari 2019, Laporan SIHA 2018, SIHA Online,
Kemenkes RI

9. Nguyen E, Craig IC, Christine GK, Erin RW. Ranozaline
in patients with type 2 diabetes and chronic
angina: A cost-effectiveness analysis and assessment
of health-related quality-of-life. Int J Cardiol.
2018.273:34–8. doi: 10.1016/j.ij card.2018.09.060.

10. Sharma SK, Mohan A, Kadhiravan T. HIV-TB coinfection:
Epidemiology, diagnosis & management,
Indian J Med Res.2005.12:550–67.

11. Setiawan Didik, Arum Dusafi tri, Githa F Galistiani,
Jurnal Ilmu Kefarmasian 264 ANGGRIANI ET AL. Indonesia
Antoinette D.I. Van Asselt, Maarten J Postma, Health
Related Quality of Life of Patients with HPV-related
cancers in Indonesia, HPV Vaccination in Indonesia: A
health –economic & comparative perspective (Groningen),
University of Groningen, 2017.

12. Yogani I,Teguh H, Anna U, Sukamto K. Faktor-faktor
yang Berhubungan dengan Kenaikan CD4 pada Pasien
HIV yang Mendapat Highly Active Antiretroviral
Therapy dalam 6 bulan Pertama. Jurnal Penyakit
Dalam Indonesia. 2015.2(4):217-23.

13. Hadning I, Ikawati Z, Andayani TM. Stroke Treatment
Cost Analysis for Consideration on Health Cost
Determination Using INA- CBGs. Int J Public Health
Sci.2015.4(4): 288–93.

14. Kementrian Kesehatan Republik Indonesia. Pedoman
Penerapan Kajian Farmakoekonomi. Kementrian
Kesehatan Republik Indonesia; 2013.

15. Makhinova T, Rascati K. Pharmacoeconomics Education
in US Colleges and Schools of Pharmacy. Am J
Pharm Educ. 2013.77(7):1–5
Published
2020-10-28
How to Cite
ANGGRIANI, Yusi et al. Cost Effectiveness Analysis of Combination Treatment Zidovudin, Lamivudin, Nevirapin and Combination Tenofovir, Lamivudin, Efavirenz HIV/AIDS Patients in Bekasi Hospital. JURNAL ILMU KEFARMASIAN INDONESIA, [S.l.], v. 18, n. 2, p. 259-264, oct. 2020. ISSN 2614-6495. Available at: <http://jifi.farmasi.univpancasila.ac.id/index.php/jifi/article/view/905>. Date accessed: 05 nov. 2024. doi: https://doi.org/10.35814/jifi.v18i2.905.
Citation Formats
Issue
Vol 18 No 2 (2020): JIFI
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.